title: First-line therapy of mutated non-small cell lung cancer: an update.
abstract: Currently, many treatment options and new targets for cancer therapies for patients with advanced non-small cell lung cancer (NSCLC) are being evaluated. This article discusses in detail the significance of first-line and second-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and inhibitors of the vascular endothelial growth factor receptor (VEGFR) and EML4-ALK. Furthermore, the article summarizes the implications and future prospects of using molecular testing in the field of NSCLC with focus on EGFR mutations, KRAS mutation, EML4-ALK fusion gene detection, and EGFR expression.
authors.affiliation: Medizinische Klinik und Poliklinik I, Fetscherstrasse 74, Dresden, Germany. jan.stoehlmacher@uniklinikum-dresden.de
authors.forename: Jan
authors.initials: J
authors.lastname: Stöhlmacher-Williams
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics; D025202:Molecular Diagnostic Techniques / Q000639:trends*
chemical_list: D000970:Antineoplastic Agents